Taiwania Capital

Taiwania Capital is a venture capital firm based in Taipei City, Taiwan, focused on fostering economic growth in Taiwan by partnering with companies worldwide. The firm manages multiple funds, including the Taiwania Capital Buffalo Fund VI and the Taiwania Central and Eastern Europe Fund, both launched in 2022. These funds invest in a diverse range of sectors, such as business products, services, information technology, consumer products, financial services, and healthcare. Taiwania Capital's investment strategy spans various regions, including the United States, Japan, Israel, Eastern Europe, and Northern Europe, aiming to support early-stage companies and contribute to the global investment landscape.

Michael Huang

Managing Partner

Steven Lee

Managing Partner of Tech Fund

Huang Lee

Managing Partner, Tech Fund

Ita Lu

Managing Partner, Tech Fund

Jerome Shen

General Partner

David Weng

Chief Executive Officer & General Partner, Tech Fund

47 past transactions

Ethernovia

Series A in 2023
Developing an Ethernet system sophisticated enough to process the bandwidth demands of the future requires expert integration at multiple levels.By unifying the vehicle network, Ethernovia system has the power to dramatically alter how cars are designed and built.

Light Field Lab

Series B in 2023
Light Field Lab, Inc. develops holographic capture display technology systems. It offers integrated processing and imaging solutions that allow immersive visuals to be delivered over commercial network speeds. The company also develops a universal application programming interface to streamline the process of bringing existing content to a light field display with holographic media. Light Field Lab, Inc. was incorporated in 2016 and is based in Morgan Hill, California.

Cognito Health

Convertible Note in 2022
Cognito Health improves the healthcare environment by increasing value for patients and healthcare systems. They continuously monitor patients using predictive algorithms to inform their staff about potential bed exits and repositioning needs.

Fractyl Health

Series F in 2022
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

Avesha

Funding Round in 2022
Avesha is a technology platform that enables application workloads to disaggregate across cloud, multi-cloud, and edge locations. Enterprises can improve business outcomes by enabling more automation, real-time use cases, and high performance/low latency applications by distributing data and application logic closer to the end-users. The Avesha SNAP (Smart Network Application Platform) creates a virtual overlay on any network underlay. The company was founded in 2019 and is headquartered in Burlington, Massachusetts.

FIGUR8

Convertible Note in 2022
FIGUR8, Inc. is a Boston-based company established in 2016 that specializes in manufacturing wearable sensors designed to measure body movement as a biomarker for musculoskeletal-related conditions. The company also offers a platform that tracks and analyzes musculoskeletal health data, aiming to provide insights into human movement. Founded by a team of engineers, researchers, and designers with backgrounds in wearable computing, digital health, and sports science, FIGUR8 focuses on making advanced movement analysis accessible to a broader audience, moving beyond the elite users to everyday individuals.

Verana Networks

Series B in 2022
Verana Networks develops an innovative 5G Radio Access Network solution for service providers that have licensed millimeter wave (mmWave) spectrum. The company focuses on enabling 5G in mmWave spectrum because that is where the largest amount of new spectrum is. For 5G to succeed, it must deliver a 10X-50X increase in speed and capacity. Blazing fast speed and an increase in capacity enable new applications, these new applications create incremental revenue, and incremental revenue is essential to support the business case for 5G.

Nanolive

Series C in 2022
Nanolive SA designs and develops devices that scan living cells. The company offers 3D Cell Explorer that allows users to explore the inside of a living cell in 3D without the need for labeling or other invasive methods. Its device scans cell division, cell organelles and cell morphology, cell differentiation, cell-cell interaction, intracellular trafficking, cellular remodeling processes, cell death (apoptosis or necrosis), drug monitoring, and in vitro fertilization. Nanolive SA was incorporated in 2013 and is headquartered in Ecublens, Switzerland.

Light Field Lab

Funding Round in 2022
Light Field Lab, Inc. develops holographic capture display technology systems. It offers integrated processing and imaging solutions that allow immersive visuals to be delivered over commercial network speeds. The company also develops a universal application programming interface to streamline the process of bringing existing content to a light field display with holographic media. Light Field Lab, Inc. was incorporated in 2016 and is based in Morgan Hill, California.

Canner

Seed Round in 2022
Make CMS Simple | Agile Content Management System for faster delivery and stability with any data sources.

Windgap Medical

Series B in 2022
WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack. The company was established in 2011 and is headquartered in Somerville, Massachusetts.
Pavilion Data Systems Inc. specializes in the design and development of NVMe-over-Fabric storage platforms that cater to massively-parallel applications. The company offers innovative solutions, including OPENCHOICE, which revolutionizes traditional storage procurement and deployment methods, and Pavilion Data OS, enabling Internet and SaaS companies, cloud service providers, and enterprises to efficiently manage critical applications. Pavilion's products deliver exceptional storage performance and density while avoiding the complexities associated with legacy all-flash arrays. By utilizing Hyperparallel Flash Arrays, which incorporate multiple controllers to maximize the advantages of flash technology, Pavilion achieves ultra-low latency and linear scalability, addressing the growing demand for enhanced data throughput across various sectors, including financial services, government, media, and research. Founded in 2011 and headquartered in San Jose, California, Pavilion Data Systems also maintains offices in Schiphol, the Netherlands, and Pune, India.

Appaegis

Seed Round in 2021
Appaegis simplifies enterprise data access while enforcing strong zero-trust security for remote access. Its patent-pending solution protects data access and gives administrators full control over how enterprise data is used. The company was founded by security veterans with successful security track records.

Landing AI

Series A in 2021
Landing.AI (Us) Corp. develops artificial intelligence transformation programs for manufacturing industry. The company develops solutions around visual inspection, controlling and automating, calibration and tuning, and automated issue identification for large manufacturer partners. It serves manufacturing, retail / ecommerce, automotive, agriculture, telecommunications, and pharmaceutical industries. The company was incorporated in 2017 and is based in Palo Alto, California.

Ethernovia

Series A in 2021
Developing an Ethernet system sophisticated enough to process the bandwidth demands of the future requires expert integration at multiple levels.By unifying the vehicle network, Ethernovia system has the power to dramatically alter how cars are designed and built.
Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders.

AEye

Post in 2021
AEye, Inc. specializes in developing vision hardware, software, and algorithms tailored for autonomous vehicles. The company is known for its innovative iDAR platform, which integrates LiDAR, computer vision, and artificial intelligence to enhance perception and motion planning for advanced driver assistance systems (ADAS) and autonomous vehicles. AEye's product offerings include the 4Sight A and 4Sight M sensors, as well as the AE100 Robotic Perception System and AE200, which are designed to meet the demands of the mobility market with modular and high-performance features. Since its inception in 2013 and a name change in 2016, AEye has established itself as a leader in intelligent sensing technology, securing investment from prestigious firms such as Kleiner Perkins and Intel Capital. The company is headquartered in Dublin, California, within the San Francisco Bay Area.

SafeLiShare

Seed Round in 2021
SafeLiShare makes it easy and safe to unlock new business models based on the sensitive and private data and programs that you own and generate.

KDAN

Series B in 2021
Kdan Mobile Software Ltd. is a software development company established in 2009 and headquartered in Tainan City, Taiwan, with additional offices in Taipei, Huntingdon, Changsha, Beijing, and Tokyo. The company specializes in mobile software applications and online services, offering a range of productivity and creativity tools. Its flagship products include Creativity 365, a comprehensive content creation suite featuring applications like Animation Desk and Write-on Video, and Document 365, which provides document management solutions such as PDF readers and online conversion services. Kdan also offers Kdan Cloud, a collaborative workspace for file management, DottedSign for electronic signatures, and Kdan PDF SDK for developers to handle PDF files across various platforms. Other notable offerings include My Markups for web page annotation and AniZone for video publishing and community interaction. With over 200 million downloads globally, Kdan Mobile serves a diverse customer base, enhancing productivity and creativity through its innovative solutions.

FIGUR8

Series A in 2021
FIGUR8, Inc. is a Boston-based company established in 2016 that specializes in manufacturing wearable sensors designed to measure body movement as a biomarker for musculoskeletal-related conditions. The company also offers a platform that tracks and analyzes musculoskeletal health data, aiming to provide insights into human movement. Founded by a team of engineers, researchers, and designers with backgrounds in wearable computing, digital health, and sports science, FIGUR8 focuses on making advanced movement analysis accessible to a broader audience, moving beyond the elite users to everyday individuals.

Oculii

Series B in 2021
Oculii is an advanced radar sensor developer specializing in 4D radar design and fusion. 4D sensors have traditionally been the domain of high power, expensive military grade radar or laser systems. Backed by top-tier Silicon Valley angel investors and VCs - they've turned this paradigm on its head, leveraging advanced sensor fusion techniques to manufacture smarter, high precision sensors and systems. Their technology allows us to extract unprecedented accuracy, range, and 4D positioning information from commodity off the shelf low-cost radar elements, bringing high resolution radar imaging to the next frontier.

Oculii

Series B in 2021
Oculii is an advanced radar sensor developer specializing in 4D radar design and fusion. 4D sensors have traditionally been the domain of high power, expensive military grade radar or laser systems. Backed by top-tier Silicon Valley angel investors and VCs - they've turned this paradigm on its head, leveraging advanced sensor fusion techniques to manufacture smarter, high precision sensors and systems. Their technology allows us to extract unprecedented accuracy, range, and 4D positioning information from commodity off the shelf low-cost radar elements, bringing high resolution radar imaging to the next frontier.

Ubiik

Series A in 2021
Enable objects to wirelessly communicate valuable information to its users

Ubiik

Series A in 2021
Enable objects to wirelessly communicate valuable information to its users

Suono Bio

Series A in 2021
Suono Bio is developing platform technology designed to enable ultra-rapid delivery of therapeutics, including proteins and nucleic acids, to the gastrointestinal (GI) tract. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally and systemically, validating further development of the system.

Avesha

Seed Round in 2021
Avesha is a technology platform that enables application workloads to disaggregate across cloud, multi-cloud, and edge locations. Enterprises can improve business outcomes by enabling more automation, real-time use cases, and high performance/low latency applications by distributing data and application logic closer to the end-users. The Avesha SNAP (Smart Network Application Platform) creates a virtual overlay on any network underlay. The company was founded in 2019 and is headquartered in Burlington, Massachusetts.

Viracta Therapeutics

Series E in 2020
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Ambiq Micro

Series F in 2020
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

Artilux Inc.

Series B in 2020
Ushering in an age of data-driven technology Artilux Connect Series provides complete IC solutions featuring high performance with competitive cost for various optical connectivity applications. Our product portfolios cover short range 10-40G consumer usages, to long range 100G data center links. We embed advanced optical and RF technology into every wire to enable seamless and instant data transfer in our living room or up in the cloud.

Fractyl Health

Series E in 2020
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.

C4 Therapeutics

Series B in 2020
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

ARRIS

Series B in 2020
Arris Composites, Inc. is an industrial engineering company that develops and manufactures carbon fiber composites designed for mass market applications. Founded in 2017 and headquartered in Berkeley, California, the company specializes in providing advanced composite materials for the aerospace, automotive, and consumer product sectors. Arris Composites focuses on innovative solutions that enhance performance and efficiency across various industries.

Regenacy Pharmaceuticals

Series A in 2020
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, that focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology conditions. Established in 2016, the company is advancing a novel, disease-modifying approach that aims to restore peripheral nerve function rather than merely managing pain and symptoms. Its lead compound, ricolinostat, is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 and has the potential to be a first-in-class treatment. Currently, ricolinostat is positioned to enter Phase 2 clinical trials, with ongoing investigations targeting diabetic, chemotherapy-induced, and inherited peripheral neuropathies. The research is supported by preclinical studies that provide compelling evidence for the restoration of normal nerve function.

Landing AI

Convertible Note in 2020
Landing.AI (Us) Corp. develops artificial intelligence transformation programs for manufacturing industry. The company develops solutions around visual inspection, controlling and automating, calibration and tuning, and automated issue identification for large manufacturer partners. It serves manufacturing, retail / ecommerce, automotive, agriculture, telecommunications, and pharmaceutical industries. The company was incorporated in 2017 and is based in Palo Alto, California.

AEye

Convertible Note in 2020
AEye, Inc. specializes in developing vision hardware, software, and algorithms tailored for autonomous vehicles. The company is known for its innovative iDAR platform, which integrates LiDAR, computer vision, and artificial intelligence to enhance perception and motion planning for advanced driver assistance systems (ADAS) and autonomous vehicles. AEye's product offerings include the 4Sight A and 4Sight M sensors, as well as the AE100 Robotic Perception System and AE200, which are designed to meet the demands of the mobility market with modular and high-performance features. Since its inception in 2013 and a name change in 2016, AEye has established itself as a leader in intelligent sensing technology, securing investment from prestigious firms such as Kleiner Perkins and Intel Capital. The company is headquartered in Dublin, California, within the San Francisco Bay Area.

Metanoia Communications

Venture Round in 2020
Metanoia Communications (”Metanoia”) was established in Hsinchu Science Park, Taiwan in 2004. Metanoia develops semiconductor and software solutions to the Wireline broadband market and the in-home networking market, providing very high-speed PHY chipsets to the broadband manufacturers. Metanoia combines “state of the art” system architecture and algorithm expertise with extensive integrated circuit design capabilites to deliver a broad range of fixed line communication products for access and In-home applications. Their portfolio includes products for the xDSL markets (more specifically for the VDSL2 and the upcoming G.fast markets), and the G.hn market.

DSP Concepts Inc.

Series B in 2020
DSP Concepts is unleashing the power of sound Sound gives us context. Next generation technology depends on intelligent audio input to help drive decisions. Noisy, windy envinroments prevent intelligent recognition of audio context. Each product demands different acoustic tuning. Our world class customers depend on us to bring them differentiation and best in class processing solutions tuneable to their form factor. Our solutions are built around Audio Weaver, the only processor agnostic platform for efficient embedded audio processing. Along with our proprietary algorithms, we collaborate with 3rd party algorithm providers to bring a full solution for your products. Reduce audio development time by 90% and bring amazing products to market faster. Clientele include the most prestigious names in the industry: Sirius/XM, Tesla, Porsche, GoPro, Daimler, Samsung, and Facebook.

Tripresso

Series A in 2020
Tripresso is an online travel agent (OTA) mainly focus on package tour products. It started off by offering an online marketplace for package tour suppliers such as Lions Travel and Richmond, and it also builds a simple search engine for end customers to find suitable products. After that, it expands the product scope to hotels, flight tickets, and customized travel plans for outbound travel. In 2018, Tripresso launched a proprietary software-as-a-service (SaaS) system, TripSaaS, which allows brick-and-mortar travel agencies to manage websites, list products, and manage orders and customer relationships to enhance operational efficiency. The company was founded in 2013 in Taipei, Taiwan.

Viracta Therapeutics

Series D in 2019
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Pavilion Data Systems Inc. specializes in the design and development of NVMe-over-Fabric storage platforms that cater to massively-parallel applications. The company offers innovative solutions, including OPENCHOICE, which revolutionizes traditional storage procurement and deployment methods, and Pavilion Data OS, enabling Internet and SaaS companies, cloud service providers, and enterprises to efficiently manage critical applications. Pavilion's products deliver exceptional storage performance and density while avoiding the complexities associated with legacy all-flash arrays. By utilizing Hyperparallel Flash Arrays, which incorporate multiple controllers to maximize the advantages of flash technology, Pavilion achieves ultra-low latency and linear scalability, addressing the growing demand for enhanced data throughput across various sectors, including financial services, government, media, and research. Founded in 2011 and headquartered in San Jose, California, Pavilion Data Systems also maintains offices in Schiphol, the Netherlands, and Pune, India.

Light Field Lab

Series A in 2019
Light Field Lab, Inc. develops holographic capture display technology systems. It offers integrated processing and imaging solutions that allow immersive visuals to be delivered over commercial network speeds. The company also develops a universal application programming interface to streamline the process of bringing existing content to a light field display with holographic media. Light Field Lab, Inc. was incorporated in 2016 and is based in Morgan Hill, California.

Frequency Therapeutics

Series C in 2019
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Ambiq Micro

Convertible Note in 2019
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.

Frequency Therapeutics

Series B in 2019
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

AEye

Series B in 2018
AEye, Inc. specializes in developing vision hardware, software, and algorithms tailored for autonomous vehicles. The company is known for its innovative iDAR platform, which integrates LiDAR, computer vision, and artificial intelligence to enhance perception and motion planning for advanced driver assistance systems (ADAS) and autonomous vehicles. AEye's product offerings include the 4Sight A and 4Sight M sensors, as well as the AE100 Robotic Perception System and AE200, which are designed to meet the demands of the mobility market with modular and high-performance features. Since its inception in 2013 and a name change in 2016, AEye has established itself as a leader in intelligent sensing technology, securing investment from prestigious firms such as Kleiner Perkins and Intel Capital. The company is headquartered in Dublin, California, within the San Francisco Bay Area.

Cognito Health

Series A in 2018
Cognito Health improves the healthcare environment by increasing value for patients and healthcare systems. They continuously monitor patients using predictive algorithms to inform their staff about potential bed exits and repositioning needs.

Ambiq Micro

Series E in 2018
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics. Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low power semiconductors are the key to the future of electronics. Through the use of their pioneering ultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility.